Theravance (THRX) Halted For Trading Ahead of FDA Meeting
More News related to THRX
- Theravance to Present at the Deutsche Bank 2009 Biotech Boston Confab
- Theravance Announces New Employment Inducement Awards
- Theravance (THRX) MAA for Telavarion Validated by EMEA
- Theravance Announces That EMEA Has Completed the Validation Phase for the Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections
- Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
More News related to FDA
- Spectranetics (SPNC) Receives U.S. FDA OK for VisiSheath Dilator Sheath Device
- Endo Pharmaceuticals (ENDP) Receives Complete Response Letter From FDA Regarding AVEED
- Simcere Pharma (SCR) Rabies Vaccine to be Investigated by China's SFDA
- Cubist Pharmaceuticals (CBST) Temporarily Suspends Enrollment In One Trial After More Deaths
- AstraZeneca (AZN) and Targacept (TRGT) To Collaborate to Develop and Commercialize TC-5214 MDD Drug
Theravance, Inc. (Nasdaq: THRX) announced that NASDAQ halted trading of Theravance common stock this morning, November 19, 2008.
The Anti-Infective Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) meets today to review and discuss the company's New Drug Application (NDA) for telavancin, a novel, bactericidal, once-daily injectable investigational antibiotic for the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA).
Related Categories
FDAStocks Mentioned
+0.21Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
